<span id="midArticle_start"/>May 5 (Reuters) - Zeltia SA :
<span id="midArticle_0"/>* Says US FDA (Food and Drug Administration) extends bythree months the deadline for completion of priority review ofthe application for Yondelis registration
<span id="midArticle_1"/>* New deadline for priority review of Yondelis for thetreatment of soft tissue sarcoma is Oct. 24Source text for Eikon:
<span id="midArticle_2"/>
<span id="midArticle_3"/>Further company coverage: (Gdynia Newsroom)
<span id="midArticle_4"/>
<span id="midArticle_0"/>* Says US FDA (Food and Drug Administration) extends bythree months the deadline for completion of priority review ofthe application for Yondelis registration
<span id="midArticle_1"/>* New deadline for priority review of Yondelis for thetreatment of soft tissue sarcoma is Oct. 24Source text for Eikon:
<span id="midArticle_2"/>
<span id="midArticle_3"/>Further company coverage: (Gdynia Newsroom)
<span id="midArticle_4"/>
via Smart Health Shop Forum http://ift.tt/1GXm8Tt
No comments:
Post a Comment